Vivani Medical (VANI) Price & Analysis

Compare

766 Followers

VANI Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.91 - $1.80

Previous CloseN/A

Volume36.09K

Average Volume (3M)144.69K

Market Cap

$72.87M

Enterprise Value$88.25M

Total Cash (Recent Filing)$6.79M

Total Debt (Recent Filing)$18.62M

Price to Earnings (P/E)―

Beta0.94

Next Earnings

Nov 18, 2025

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding59,243,904

10 Day Avg. Volume65,319

30 Day Avg. Volume144,687

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.21

Enterprise Value/Revenue221.73

Enterprise Value/Gross Profit-5.88K

Enterprise Value/Ebitda-3.33

Forecast

1Y Price Target

$4.00

Price Target Upside233.33% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Market OpportunityThere is a significant market opportunity with a 3-6 month semaglutide implant for weight loss.

Product DevelopmentThe strategic prioritization of NPM-139 is seen as prudent due to existing weight loss and safety data, which could be efficiently leveraged for future regulatory filings.

Bears Say

Clinical Trials RiskRisks include failure of NPM-139 in clinical trials, failure to secure regulatory approval, failure to achieve commercial success due to market size, penetration rate, and competition, and dilution risk.

Regulatory Approval RiskRisks include the potential failure of NPM-115 in clinical trials, failure to secure regulatory approval, failure to achieve commercial success, and dilution risk.

Vivani Medical News

Vivani Medical reports results from LIBERATE-1 study of NPM-115

Vivani Medical (VANI) reported results from the LIBERATE-1 clinical study, the Phase 1 study of the exenatide GLP-1...

22d ago

VANI

Vivani Medical’s Strategic Focus and Promising Developments Drive Buy Rating

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Vivani Medical and keeping the price target...

12d ago

VANI

Vivani Medical Reports Q2 2025 Results and $10M Financing

Vivani Medical, Inc. ( ($VANI) ) has released its Q2 earnings. Here is a breakdown of the information...

13d ago

VANI

Vivani Medical Secures $10M Through Share Purchase Agreement

Vivani Medical ( ($VANI) ) has shared an update. On August 11, 2025, Vivani Medical entered into a...

13d ago

VANI

Vivani Medical’s Strategic Advancements and Market Potential Drive Buy Rating

Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Vivani Medical. The associated price target...

21d ago

VANI

Vivani Medical’s Promising Trial Results and Market Potential Drive Buy Rating

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Vivani Medical, with...

22d ago

VANI

Vivani Medical Announces Positive Phase 1 Study Results

Vivani Medical ( ($VANI) ) has shared an update. On August 5, 2025, Vivani Medical announced positive results...

22d ago

VANI

Vivani Medical Holds 2025 Annual Stockholders Meeting

Vivani Medical ( ($VANI) ) has issued an announcement. The 2025 Annual Meeting of Stockholders of Vivani Medical,...

2M ago

VANI

Vivani Medical Updates on Exenatide Implant Progress

Vivani Medical ( ($VANI) ) has issued an announcement. Vivani Medical has released a corporate slide presentation to...

2M ago

VANI

Vivani Medical Appoints New CFO Amid Leadership Change

Vivani Medical ( ($VANI) ) just unveiled an update. On June 10, 2025, Brigid Makes announced her resignation...

3M ago

VANI

Vivani Medical appoints Baldor as Chief Financial Officer

Vivani Medical (VANI) announced the appointment of Anthony Baldor as Chief Financial Officer. Baldor succeeds Brigid Makes, who...

3M ago

VANI

Vivani Medical Announces Spin-Off of Cortigent Subsidiary

Vivani Medical ( ($VANI) ) has issued an update. On May 29, 2025, Vivani Medical announced the planned...

3M ago

VANI

Vivani Medical files Form 10 registration statement for Cortigent spin-off

Vivani Medical (VANI) announced that Cortigent, a wholly owned subsidiary of the Company that develops brain implant devices...

3M ago

VANI

Vivani Medical, Okava expand collaboration to develop OKV-119 for dogs

Vivani Medical (VANI) and Okava Pharmaceuticals announced an expansion of their collaboration to include dogs in the development...

4M ago

VANI

VANI FAQ

What was Vivani Medical’s price range in the past 12 months?

Vivani Medical lowest stock price was $0.91 and its highest was $1.80 in the past 12 months.

What is Vivani Medical’s market cap?

Vivani Medical’s market cap is $72.87M.

When is Vivani Medical’s upcoming earnings report date?

Vivani Medical’s upcoming earnings report date is Nov 18, 2025 which is in 83 days.

How were Vivani Medical’s earnings last quarter?

Vivani Medical released its earnings results on Aug 13, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.1 by -$0.02.

Is Vivani Medical overvalued?

According to Wall Street analysts Vivani Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vivani Medical pay dividends?

Vivani Medical does not currently pay dividends.

What is Vivani Medical’s EPS estimate?

Vivani Medical’s EPS estimate is -0.1.

How many shares outstanding does Vivani Medical have?

Vivani Medical has 59,243,904 shares outstanding.

What happened to Vivani Medical’s price movement after its last earnings report?

Vivani Medical reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.1. Following the earnings report the stock price went up 0.794%.

Which hedge fund is a major shareholder of Vivani Medical?

Currently, no hedge funds are holding shares in VANI

Vivani Medical Stock Smart Score

Underperform

Fundamentals

Return on Equity

-177.75%

Trailing 12-Months

Asset Growth

-40.06%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vivani Medical

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Vivani Medical (VANI) Earnings & Revenues

Historic Earnings Reports

VANI Stock 12 Month Forecast

Average Price Target

$4.00

▲(233.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","1.25":"$1.25","2.5":"$2.5","3.75":"$3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.33,1.5353846153846153,1.7407692307692308,1.9461538461538463,2.1515384615384616,2.356923076923077,2.5623076923076926,2.767692307692308,2.973076923076923,3.1784615384615384,3.3838461538461537,3.5892307692307694,3.7946153846153847,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.33,1.5353846153846153,1.7407692307692308,1.9461538461538463,2.1515384615384616,2.356923076923077,2.5623076923076926,2.767692307692308,2.973076923076923,3.1784615384615384,3.3838461538461537,3.5892307692307694,3.7946153846153847,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.33,1.5353846153846153,1.7407692307692308,1.9461538461538463,2.1515384615384616,2.356923076923077,2.5623076923076926,2.767692307692308,2.973076923076923,3.1784615384615384,3.3838461538461537,3.5892307692307694,3.7946153846153847,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.09,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >